

Triple Switch Prostate Trial Kickoff

CCTG-PR.26: A Joint CCTG and SWOG Clinical Trial

FRIDAY, SEPT 19 • 5:30 – 6:30 PM CT • COMISKEY (CONCOURSE LEVEL)

CCTG-PR.26, A Randomized Phase III Clinical Trial for the Addition of Docetaxel to ARPI in Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) and Suboptimal PSA Response

Triple Switch (CCTG-PR.26) was co-developed by Dr. Michael Ong (CCTG) and Dr. Alexandra Sokolova (SWOG) and is co-led by SWOG and CCTG.

The trial enrolls patients with mCSPC at a unique time point in their journey – 6 to 12 months after starting therapy, before disease progression.


This kickoff session will educate members on how to approach the enrollment challenges posed by this unusual registration timing.

Drs. Ong and Sokolova will also

✓ discuss how they have been successful in identifying patients	✓ share study rationale data that can be used when presenting Triple Switch to patients	✓ share the experience of the first patient enrolled	✓ discuss unique features of the protocol	✓ answer questions about the protocol, data forms, and more
--	--	---	--	--

Study Population

- mCSPC (any volume/risk)
- Received 6-12 months ADT
- Received ≥ 4 months ARPI:
 - abiraterone
 - enzalutamide
 - OR darolutamide
- PSA ≥ 5 prior to ADT
- PSA ≥ 0.2 at enrollment
- Docetaxel naïve / eligible



STUDY CHAIRS

Alexandra
Sokolova,
MD



Michael
Ong, MD